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In December 2020, the National Institute for Health and 
Care Excellence (NICE) reviewed the evidence and updated 
their recommendations on intermittently scanned (com-
monly known as Flash) and Continuous Glucose Monitoring 
(CGM) during pregnancy for women with type 1 diabetes.1 
The NICE guidelines now recommend offering CGM to all 
pregnant women with type 1 diabetes to help them meet their 
pregnancy glucose targets and improve neonatal outcomes. 
Their evidence review, based on the CONCEPTT randomised 
trial2 and a Swedish observational study3 found that, com-
pared to capillary glucose monitoring, CGM resulted in more 
women achieving their blood glucose targets, fewer caesar-
ean sections and fewer neonatal intensive care admissions. 
Health economic modelling found that while Flash was the 
cheapest option (compared to CGM and capillary glucose 
monitoring) the quality of the evidence for Flash was very 
low, with concerns about clinical benefit, accuracy in the low 
glucose range and the number of daily capillary glucose tests 
required to use Flash safely. They concluded that there was 
high quality evidence that CGM was associated with better 
clinical outcomes and a 94% chance of CGM being cheaper 
than capillary glucose testing. They also updated the recom-
mendations on education and support for pregnant women 
using CGM or Flash to ensure they get the full benefit. Online 
resources (user videos and webinars) to support diabetes self 
management using technology before and during pregnancy 
are available to support implementation of the NICE guide-
lines (Figure 1). The Diabetes Technology Network (DTN) 
has also produced Top Tips for CGM users and Best Practice 
Guidelines for health care professionals (https://abcd.care/
dtn/CGM). NICE did not provide clear guidance for time- in- 
range pregnancy glucose targets, which are more than 70% 
CGM time- in- range (TIR 3.5– 7.8  mmol/L), less than 25% 
time- above- range (TAR  >  7.8  mmol/L) and less than 4% 
time- below- range (TBR  <  3.5  mmol/L) in type 1 diabetes 
pregnancy.4
It is increasingly clear that measures to reduce the pro-
gression from gestational diabetes mellitus (GDM) to type 
2 diabetes are urgently needed. Another very welcome 
NICE guidance update is to offer referral into the NHS 
Diabetes Prevention Programme for women with a previ-
ous GDM pregnancy. Women with GDM were previously 
eligible based on an elevated postnatal fasting plasma glu-
cose (>6.0  mmol/L) or HbA1c (39– 47  mmol/mol; 5.7%– 
6.4%). Eligibility criteria for the NHS Diabetes Prevention 
Programme has been expanded to all women with a history 
of previous gestational diabetes, including those with normo-
glycaemia (FPG < 5.5 mmol/L or HbA1c < 42 mmol/mol). 
There is no time limit on when the GDM pregnancy occurred, 
so all women with a history of previous GDM are eligible 
but it is recommended that the HbA1c be carried out within 
the past 12 months. This supports the widespread view that 
a major shift is needed in the clinical management of GDM; 
focusing not only on the short- term obstetric and neonatal 
complications but also including increased emphasis on the 
longer- term maternal risks of type 2 diabetes and cardiometa-
bolic disorders.5 This is highlighted by the recent distribution 
of coronavirus shielding letters to women with a history of 
previous GDM. Women with previous GDM (within the past 
decade) are classed as clinically extremely vulnerable (CEV) 
and advised to have a HbA1c as soon as feasible unless per-
formed within the past 12 months.6 Nationwide implemen-
tation of postnatal HbA1c measurements at 3– 6  months in 
conjunction with infant vaccinations, instead of or in addition 
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to a fasting plasma glucose at 6– 12 weeks, may further im-
prove postnatal GDM care.
The annual National Pregnancy in Diabetes (NPID) audit 
measures the quality of antenatal care according to the stan-
dards set out by NICE, providing pregnancy outcome in-
formation for individual maternity units, regional clinical 
networks and women with diabetes.7 The NPID team has 
recently published data on 17,375 pregnancies in 15,290 
women with diabetes, the largest contemporary population- 
based diabetes pregnancy cohort.8 These data confirm that 
half of all pregnancies in women with pre- existing diabetes 
occur in women with type 2 diabetes with a striking socio- 
economic gradient as noted by the seven times higher rate 
of conceptions (41.5 vs. 5.7%) among women with type 2 
diabetes living in the most compared to the least deprived 
regions. Women with type 2 diabetes were more likely than 
those with type 1 diabetes to take potentially harmful statins 
(5.3 vs 1.5%) and ACE/ARB inhibitors (4.1 vs. 1.2%) at 
conception suggesting inadequate attention to contraception 
and pregnancy planning. Information and advice about the 
importance of contraception and pregnancy planning is not 
reaching the majority of women with type 2 diabetes. Even 
though two thirds of women with type 2 diabetes were taking 
metformin and hence engaging with healthcare profession-
als, only one in five were taking 5 mg folic acid and treated 
with insulin before pregnancy. Thus, almost two thirds of 
pregnant women with type 2 diabetes enter pregnancy with 
HbA1c levels above 48 mmol/mol (6.5%). Greater emphasis 
on treating women with type 2 diabetes of reproductive years 
to target glycaemia is urgently needed. The NICE research 
recommendations identified a need for qualitative research 
focused on exploring the barriers to achieving pregnancy 
glucose targets (Box  1). Given the importance of pericon-
ception HbA1c, this could be expanded to include the pre- 
pregnancy and interpregnancy management of women with 
diabetes.
Despite clear evidence that maternal glucose levels are 
the key modifiable predictor of perinatal death,7- 9 NICE 
did not comment on the role of glucose monitoring for the 
growing numbers of pregnant women with type 2 diabetes. 
Women with type 2 diabetes are mentioned indirectly as 
‘pregnant women who are on insulin therapy but do not have 
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type 1 diabetes’. They can be considered for CGM if they 
have problematic severe hypoglycaemia (with or without 
impaired awareness of hypoglycaemia) which applies to a 
minority (2%– 3%) of women with type 2 diabetes. However, 
use of CGM or Flash can be considered for pregnant women 
with ‘unstable blood glucose levels that are causing con-
cern despite efforts to optimise glycaemic control’. Pregnant 
women with type 2 diabetes, and HbA1c  >  48  mmol/mol 
(6.5%) have, by definition, ‘unstable glucose levels’ and an 
increased risk of stillbirth and neonatal death (Odds ratio of 
3.9; 95% CI 2.5– 6.2),7,8 thus use of CGM or Flash should 
be considered for all women in this category. The ‘unsta-
ble glucose’ indication covers approximately two thirds 
of women with type 2 diabetes in early pregnancy. Whilst 
CGM is preferred to Flash because of the randomised con-
trolled trial evidence and the increased risk of severe hy-
poglycaemia in type 1 diabetes pregnancy, Flash may be 
suitable for pregnant women with type 2 diabetes. More data 
regarding the clinical effectiveness of Flash and CGM and 
appropriate pregnancy glucose targets for HbA1c and CGM 
time- in- range metrics are urgently needed in type 2 diabetes 
pregnancy.
Although NICE 2015/2020 recommends aiming for an 
HbA1c of less than 48  mmol/mol both before and during 
pregnancy in all women with pre- existing diabetes, it is 
worth noting that earlier 2008 NICE guidance actually 
recommended a tighter target of aiming for HbA1c below 
43 mmol/mol (6.1%) where safely achievable. This is chal-
lenging to safely achieve in type 1 diabetes pregnancy. 
However, it may be more readily achievable before and 
during pregnancy in type 2 diabetes and during the second 
half of pregnancy in those with type 1 diabetes. In Denmark, 
the HbA1c recommendations are adjusted for advancing 
gestation; with pragmatic HbA1c targets of <50 mmol/mol 
(6.7%) before 20  weeks and <40  mmol/mol (5.8%) after 
20 weeks gestation based on data suggesting that the upper 
normal range of HbA1c in healthy pregnancy was around 
38 mmol/mol (5.6%).9,10 The American Diabetes Association 
(ADA) also recommends trimester- specific HbA1c targets; 
below 48 mmol/mol (6.5%) in the first trimester and below 
43 mmol/mol (6.1%) thereafter.10,11 Given that maternal gly-
caemia is the key modifiable predictor for adverse outcomes 
in both type 1 and type 2 diabetes pregnancy,7 NICE should 
also consider trimester- specific HbA1c targets and/or recon-
sider whether HbA1c  <  43  mmol/mol (6.1%) is applicable 
throughout type 2 diabetes pregnancy.
Overall the NICE guidelines bring good news for pregnant 
women with gestational and type 1 diabetes, but more work is 
needed to improve the pregnancy preparation and attention to 
pregnancy glucose targets, possibly requiring more stringent 
glycaemic targets, in pregnant women with type 2 diabetes. 
In addition to interventions for delaying and preventing type 
2 diabetes, more work is needed to optimise the immediate 
post- natal and annual glucose surveillance in all women with 
a previous pregnancy complicated by GDM.
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